April 1, 2017

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Key Points

Key points are not available for this paper at this time.

Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Bookmark

Cite This Study

Ettinger et al. (Sat,) studied this question.

synapsesocial.com/papers/69d7f2ae11d83f35e5ae36f8 https://doi.org/https://doi.org/10.6004/jnccn.2017.0050

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 29,483 citations
2Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial2012 · 11 citations
3SEER Cancer Statistics Review, 1975-20032006 · 11,477 citations
4NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.1996 · 71 citations
5Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib2007 · 59 citations

Bookmark